Structure

InChI Key YNWDKZIIWCEDEE-UHFFFAOYSA-N
Smile COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[n-]2)c1OC.[Na+]
InChI
InChI=1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h3-7,15H,8H2,1-2H3;/q-1;+1

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H16F2N3NaO5S
Molecular Weight 423.37
AlogP 2.88
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 7.0
Polar Surface Area 86.33
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 26.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Potassium-transporting ATPase inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - - - 94.78
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -6.01-28.18

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 1 D009369 ClinicalTrials
Lecithin Cholesterol Acyltransferase Deficiency 1 D007863 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Renal and urinary disorders
30.43
General disorders and administration site conditions
9.15
Gastrointestinal disorders
8.64
Injury, poisoning and procedural complications
5.31
Nervous system disorders
5.08
Vascular disorders
4.3
Skin and subcutaneous tissue disorders
3.91
Respiratory, thoracic and mediastinal disorders
3.88
Investigations
3.45
Cardiac disorders
3.42
Musculoskeletal and connective tissue disorders
3.38
Metabolism and nutrition disorders
3.25
Psychiatric disorders
3.17
Immune system disorders
2.93
Infections and infestations
2.4

Cross References

Resources Reference
ChEMBL CHEMBL3989559
FDA SRS 6871619Q5X
PubChem 11954257